Patents Assigned to NANJING UMAB-BIOPHARMA CO., LTD.
  • Anti-OX40 antibody
    Patent number: 11440965
    Abstract: Provided is an isolated antibody or antigen binding fragment thereof. The isolated antibody or antigen binding fragment thereof can be used to prepare a medicament for treating tumors.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: September 13, 2022
    Assignee: NANJING UMAB-BIOPHARMA CO., LTD.
    Inventors: Shifu Mo, Xun Yin, Jing Zhao
  • ISOLATED ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF AND USE OF SAME IN TUMOR TREATMENT
    Publication number: 20210269539
    Abstract: Provided is an isolated antibody or antigen binding fragment thereof. The isolated antibody or antigen binding fragment thereof can be used to prepare a medicament for treating tumors.
    Type: Application
    Filed: December 12, 2018
    Publication date: September 2, 2021
    Applicant: NANJING UMAB-BIOPHARMA CO., LTD.
    Inventors: Shifu Mo, Xun Yin, Jing Zhao
  • FUSION PROTEIN AND ITS APPLICATON IN PREPARING MEDICINE FOR TREATING TUMOR AND/OR VIRAL INFECTION
    Publication number: 20210198375
    Abstract: The present disclosure provides a fusion protein and methods thereof for preparing a pharmaceutical composition comprising the fusion protein and for methods for treating tumors and/or viral infections using said fusion proteins and compositions, wherein the fusion protein comprises an antibody or antigen-binding fragment thereof that specifically binds to human OX40 and a human interferon.
    Type: Application
    Filed: March 4, 2021
    Publication date: July 1, 2021
    Applicant: NANJING UMAB-BIOPHARMA CO., LTD.
    Inventors: Shifu Mo, Yong Zhao, Wei Xu, Zhichao Wang, Jie Yang, Liyun Gu, Dong Ding